A pharmaceutical preparation for preventing and treating fatty liver and reducing blood lipid

A technology for alcoholic fatty liver and drug, applied in the field of medicine, to achieve the effects of reducing toxic damage, improving lipid metabolism, and reducing liver lipid peroxidative damage

Inactive Publication Date: 2019-01-18
SHANDONG ACAD OF CHINESE MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The composition of saikosaponin A and lipoic acid is used to treat liver damage caused by fatty degeneration of hepatocytes caused by fatty liver, infection, drugs, metabolic disorders, etc., and there is no report or patent publication on hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical preparation for preventing and treating fatty liver and reducing blood lipid
  • A pharmaceutical preparation for preventing and treating fatty liver and reducing blood lipid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 Preparation of the composition tablet of the present invention

[0028] 1. Prescription:

[0029] Prescription 1

[0030] saikosaponin A

1g

lipoic acid

100g

microcrystalline cellulose

50g

pregelatinized starch

100g

10% PVPK30 ethanol solution

Appropriate amount

Magnesium stearate

3g

co-preparation

1000 pieces

[0031] Prescription 2

[0032] saikosaponin A

3g

lipoic acid

200g

microcrystalline cellulose

60g

pregelatinized starch

100g

10% PVPK30 ethanol solution

Appropriate amount

Magnesium stearate

3g

co-preparation

1000 pieces

[0033] 2. Preparation process:

[0034] Raw materials and auxiliary materials were crushed through 80-mesh sieve for later use; preparation of granulation solution: take PVP K30 and add medicinal ethanol with a concentration of 30-95% to make a 5-10% solution; mix raw material...

Embodiment 2

[0035] Embodiment 2 The preparation of the capsule of pharmaceutical composition of the present invention

[0036] 1. Prescription:

[0037] Prescription 1

[0038] saikosaponin A

1g

lipoic acid

100g

microcrystalline cellulose

50g

pregelatinized starch

100g

10% PVPK30 ethanol solution

Appropriate amount

Magnesium stearate

3g

co-preparation

1000 capsules

[0039] Prescription 2

[0040] saikosaponin A

3g

lipoic acid

200g

microcrystalline cellulose

60g

pregelatinized starch

100g

10% PVPK30 ethanol solution

Appropriate amount

Magnesium stearate

3g

co-preparation

1000 capsules

[0041] 2. Preparation process:

[0042]Raw materials and auxiliary materials were crushed through 80-mesh sieve for later use; preparation of granulation solution: take PVP K30 and add medicinal ethanol with a concentration of 30-95% to make a 5-10...

Embodiment 3

[0043] Embodiment 3 Preparation of pharmaceutical composition granules of the present invention

[0044] 1. Prescription:

[0045] Prescription 1:

[0046] saikosaponin A

0.5g

lipoic acid

200g

powdered sugar

1000g

2%HPMC50% ethanol solution

Appropriate amount

co-preparation

1000 packs

[0047] Prescription 2:

[0048] saikosaponin A

1g

lipoic acid

300g

powdered sugar

1200g

2%HPMC50% ethanol solution

Appropriate amount

co-preparation

1000 packs

[0049] 2. Specific steps:

[0050] Crush the raw materials and auxiliary materials through a 100-mesh sieve, and set aside; weigh the raw materials and auxiliary materials according to the prescription amount, mix the raw materials and powdered sugar in equal amounts, add an appropriate amount of 2% HPMC50% ethanol solution, and stir evenly to prepare Suitable for soft materials, pass through a 20-mesh sieve to gran...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of saikoside A and lipoic acid in preparation of drugs for preventing and treating fatty liver and hyperlipidaemia. Pharmacological studies show that the pharmaceutical preparation disclosed by the invention has the functions of significantly reducing liver lipid peroxidation injury, lowering serum total cholesterol and triglyceride levels and effectively preventing and treating fatty liver.

Description

technical field [0001] The invention relates to a pharmaceutical composition composed of saikosaponin A and lipoic acid, a preparation method thereof, and an application of the pharmaceutical composition in preventing and treating fatty liver and hyperlipidemia, belonging to the technical field of medicine. Background technique [0002] Relevant data show that the prevalence of fatty liver in adults is 5% to 9%, and it has become the second major liver disease after viral hepatitis. Malnutrition, heavy drinking, diabetes, infection, drug-induced injury, metabolic and endocrine disorders, etc. can all lead to fatty liver. With the accumulation of fat in the liver cells, it can directly cause liver function damage, liver function decline, severe liver fibrosis, and eventually liver cirrhosis, resulting in a poor prognosis. The current clinical treatment drugs for fatty liver mainly include lipid-lowering drugs (clofibrate, choline, methionine, niacin, statins, etc.), liver-pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P1/16A61P3/06A61K31/385
Inventor 孙蓉李晓骄阳刘闰平毛近隆冯群李晓宇
Owner SHANDONG ACAD OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap